Lyell Immunopharma
Lyell is a T cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors. Lyell focuses on addressing what it believes are the primary barriers that limit consistent, reliable and curative responses with adoptive T cell therapy: T cell exhaustion and loss of durable stemness, which includes proliferative capacity, ability to self-renew and ability to differentiate and eliminate solid tumors. Lyell is applying its proprietary ex vivo genetic and epigenetic reprogramming technology platforms, Gen-R and Epi-R, to address these barriers in order to develop new medicines with improved, durable, and potentially curative clinical outcomes.
Domain
lyell.com
Country
United StatesIndustry
BiotechnologyEmployees
251-500
Last Funding
$50.0M
Founded
2017
Tech Stack (16 technologies)
Frequently Asked Questions
What technologies does Lyell Immunopharma use?+
Lyell Immunopharma uses 16 technologies including Bootstrap, Font Awesome, Google Tag Manager.
What industry is Lyell Immunopharma in?+
Lyell Immunopharma operates in the Biotechnology industry.
Where is Lyell Immunopharma based?+
Lyell Immunopharma is headquartered in United States.
Explore More
Need this data at scale?
Get ready-to-use datasets: companies, technologies, and tech adoption signals across 3M+ websites.
Browse DatasetsData last updated: June 2026